{'fraction_non_alphanumeric': 0.03322259136212625, 'fraction_numerical': 0.008305647840531562, 'mean_word_length': 5.414893617021277, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Expression of serotonin receptors and role of serotonin in human prostate cancer tissue and cell lines

Increase in the number of serotonin (5‐HT) releasing neuroendocrine (NE) cells has been shown to be correlated with tumor progression, loss of androgen dependence, and poor prognosis. Serotonin is a well‐known mitogen which mediates a wide variety of physiological effects via multiple receptors, of which receptor subtype 1 (5‐HTR1) has been identified in prostate cancer (PC) cell lines. Recently, 5‐HT has been found to show growth‐promoting activity and to be functionally related to oncogenes.